Novavax completes patient registration for the study of its Covid-19 vaccine in Mexico and the US

The drug developer Novavax reported this Monday that it has completed the registration of patients for the last stage study of its Covid-19 vaccine in the United States and Mexico.

The company said last month that its vaccine was 89.3% effective in preventing Covid-19 in a UK trial, and it was almost as effective in protecting against the more highly contagious variant first discovered there.

Novavax It said it had enrolled 30,000 volunteers in the United States and Mexico.

In the last-phase trial, the company said that 20% of the participants were Latino, 13% were African-American, and 13% were 65 or older.

READ  Malaga closes a black week with 132 deaths from Covid

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.